

PROVINCIAL FUNDING SUMMARY

Ceritinib (Zykadia) for Metastatic Non-Small Cell Lung Cancer (Resubmission)
(pCODR 10094)

pERC Recommendation: Recommends

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: April 5, 2017

This information is current as of November 1, 2019.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

| PROVINCE | FUNDING STATUS | FUNDING DATE | FUNDING CRITERIA |
|----------|----------------|--------------|--|
| BC | Funded | Sept 1, 2018 | Advanced non-small cell lung cancer Laboratory confirmed anaplastic lymphoma kinase (ALK)-positive tumour defined as either IHC 3+ or FISH positive ECOG 0-2 Second-line monotherapy for disease progression on crizotinib, or in patients with intolerance to crizotinib. BC Cancer Compassionate Access Program (CAP) approval must be obtained. |
| AB | Funded | Oct 30, 2018 | For treatment as monotherapy in patients with anaplastic lymphoma kinase (ALK) positive locally advanced (not amenable to curative therapy) or metastatic NSCLC who have progressed on or who were intolerant to crizotinib. |
| SK | Funded | Aug 15, 2018 | Treatment as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have disease progression on or intolerance to crizotinib. |
| MB | Funded | Jul 19, 2018 | For treatment as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have disease progression on or intolerance to crizotinib. |

| PROVINCE | FUNDING STATUS | FUNDING DATE | FUNDING CRITERIA |
|----------|--------------------------------|--------------|---|
| ON | Funded | Oct 11, 2018 | For the treatment of anaplastic lymphoma kinase (“ALK”) - positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) in patients meeting ALL the following criteria: <ul style="list-style-type: none"> • Patient is using ceritinib as monotherapy; AND • Ceritinib is being used as second line therapy in patients who have experienced disease progression to crizotinib OR in patients who have experienced intolerance to crizotinib. |
| NS | Funded | Oct 3, 2019 | For the treatment of patients with locally advanced or metastatic anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) who experience disease progression on, or intolerance to crizotinib. Patients should have a good performance status and treatment should be continued until disease progression or unacceptable toxicity. |
| NB | Funded | Nov 30, 2018 | As monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer who experience disease progression on, or intolerance to, crizotinib. Renewal Criteria: - Written confirmation that the patient is responding to treatment. Clinical Note: 1. Treatment should be discontinued upon clinically meaningful disease progression or unacceptable toxicity. Claim Notes: 1. Disease progression on any other ALK-inhibitor following crizotinib precludes reimbursement of ceritinib. 2. Initial approval: 1 year. 3. Renewal approval: 1 year. |
| NL | Under provincial consideration | | |
| PEI | Under provincial consideration | | |

Under provincial consideration means that the province is reviewing pCODR’s recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.